ArticleInternational journal of medical sciences2026
A naturally occurring polyphenolic compound for liver cancer treatment.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a polyphenolic compound naturally found in nature, piceatannol is an analogue of resveratrol. These compounds share a common structural motif but have various substituents. Resveratrol shows anti-inflammation and anti-tumor properties, but such biological activities of the active resveratrol metabolite - piceatannol are unclear. In this study, the anti-tumor properties of piceatannol were investigated through cell viability, colony formation, migration assay, detection of reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) change, reverse transcription quantitative polymerase chain reaction (RT-qPCR), and Western blotting in human hepatocellular carcinoma cell lines. Piceatannol decreased cell viability in a dose-dependent manner. These concentrations required to inhibit 50% of activity (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.